113 related articles for article (PubMed ID: 34057118)
1. Overexpression of NF-kB as a predictor of neoadjuvant chemotherapy response in breast cancer.
Sampepajung E; Hamdani W; Sampepajung D; Prihantono P
Breast Dis; 2021; 40(S1):S45-S53. PubMed ID: 34057118
[TBL] [Abstract][Full Text] [Related]
2. The Effect of P-Glycoprotein (P-gp), Nuclear Factor-Kappa B (Nf-κb), and Aldehyde Dehydrogenase-1 (ALDH-1) Expression on Metastases, Recurrence and Survival in Advanced Breast Cancer Patients.
Prajoko YW; Aryandono T
Asian Pac J Cancer Prev; 2019 May; 20(5):1511-1518. PubMed ID: 31128056
[TBL] [Abstract][Full Text] [Related]
3. Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients.
Montagut C; Tusquets I; Ferrer B; Corominas JM; Bellosillo B; Campas C; Suarez M; Fabregat X; Campo E; Gascon P; Serrano S; Fernandez PL; Rovira A; Albanell J
Endocr Relat Cancer; 2006 Jun; 13(2):607-16. PubMed ID: 16728586
[TBL] [Abstract][Full Text] [Related]
4. The relationship between NFKB, HER2, ER expression and anthracycline -based neoadjuvan chemotherapy response in local advanced stadium breast cancer: A cohort study in Eastern Indonesia.
Indra ; Manginstar C; Islam AA; Sampepajung D; Hamdani W; Bukhari A; Syamsu SA; Prihantono ; Smaradania N; Faruk M
Ann Med Surg (Lond); 2021 Mar; 63():102164. PubMed ID: 33664949
[TBL] [Abstract][Full Text] [Related]
5. Strong cytoplasmic expression of NF-κB/p65 correlates with a good prognosis in patients with triple-negative breast cancer.
Baba M; Takahashi M; Yamashiro K; Yokoo H; Fukai M; Sato M; Hosoda M; Kamiyama T; Taketomi A; Yamashita H
Surg Today; 2016 Jul; 46(7):843-51. PubMed ID: 26494004
[TBL] [Abstract][Full Text] [Related]
6. Expression of nuclear factor kappa B (NF-κB) as a predictor of poor pathologic response to chemotherapy in patients with locally advanced breast cancer.
Prajoko YW; Aryandono T
Asian Pac J Cancer Prev; 2014; 15(2):595-8. PubMed ID: 24568463
[TBL] [Abstract][Full Text] [Related]
7. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
Buchholz TA; Garg AK; Chakravarti N; Aggarwal BB; Esteva FJ; Kuerer HM; Singletary SE; Hortobagyi GN; Pusztai L; Cristofanilli M; Sahin AA
Clin Cancer Res; 2005 Dec; 11(23):8398-402. PubMed ID: 16322301
[TBL] [Abstract][Full Text] [Related]
8. PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer.
Ohara AM; Naoi Y; Shimazu K; Kagara N; Shimoda M; Tanei T; Miyake T; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2019 Feb; 173(3):533-543. PubMed ID: 30361874
[TBL] [Abstract][Full Text] [Related]
9. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
[TBL] [Abstract][Full Text] [Related]
11. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
13. Nuclear NF-κB/p65 expression and response to neoadjuvant chemotherapy in breast cancer.
Jones RL; Rojo F; A'Hern R; Villena N; Salter J; Corominas JM; Servitja S; Smith IE; Rovira A; Reis-Filho JS; Dowsett M; Albanell J
J Clin Pathol; 2011 Feb; 64(2):130-5. PubMed ID: 21148141
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
[TBL] [Abstract][Full Text] [Related]
15. NF-κB/p65 expression before and after treatment in rectal cancer patients undergoing neoadjuvant (chemo)radiotherapy and surgery: prognostic marker for disease progression and survival.
Voboril R; Rychterova V; Voborilova J; Kubecova M; Fanta J; Dvorak J
Neoplasma; 2016; 63(3):462-70. PubMed ID: 26952512
[TBL] [Abstract][Full Text] [Related]
16. MYC Amplification as a Predictive Factor of Complete Pathologic Response to Docetaxel-based Neoadjuvant Chemotherapy for Breast Cancer.
Pereira CBL; Leal MF; Abdelhay ESFW; Demachki S; Assumpção PP; de Souza MC; Moreira-Nunes CA; Tanaka AMDS; Smith MC; Burbano RR
Clin Breast Cancer; 2017 Jun; 17(3):188-194. PubMed ID: 28089283
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis.
Miglietta L; Vanella P; Canobbio L; Naso C; Cerisola N; Meszaros P; Parodi MA; Morabito F
Oncology; 2010; 79(3-4):255-61. PubMed ID: 21372600
[TBL] [Abstract][Full Text] [Related]
18. Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in Northeast China.
Lv M; Li B; Li Y; Mao X; Yao F; Jin F
Asian Pac J Cancer Prev; 2011; 12(9):2411-7. PubMed ID: 22296393
[TBL] [Abstract][Full Text] [Related]
19. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
[TBL] [Abstract][Full Text] [Related]
20. HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Yao L; Liu Y; Li Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Ann Oncol; 2011 Jun; 22(6):1326-1331. PubMed ID: 21196440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
